SEARCH:   Advanced

Blood, 15 March 2005, Vol. 105, No. 6, pp. 2510-2518. Prepublished online as a Blood First Edition Paper on November 30, 2004; DOI 10.1182/blood-2004-08-3052. This Article Full Text Full Text (PDF) All Versions of this Article: 2004-08-3052v1 105/6/2510    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Godfrey, A. Articles by Boshoff, C. Search for Related Content PubMed PubMed Citation Articles by Godfrey, A. Articles by Boshoff, C. Related Collections Neoplasia Transfusion Medicine Apoptosis Gene Therapy Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  NEOPLASIA Inhibiting primary effusion lymphoma by lentiviral vectors encoding short hairpin RNA Andrew Godfrey, John Anderson, Antigoni Papanastasiou, Yasu Takeuchi, and Chris Boshoff From the Cancer Research United Kingdom Viral Oncology Group, Wolfson Institute for Biomedical Research; Unit of Molecular Haematology and Cancer Biology, Institute of Child Health; and Windeyer Institute for Medical Sciences, University College London, London, United Kingdom. We use lentiviral-delivered RNA interference (RNAi) to inhibit the growth of a model of primary effusion lymphoma (PEL) in vitro and in vivo. RNAi is a phenomenon allowing the sequence-specific targeting and silencing of exogenous and endogenous gene expression and is being applied to inhibit viral replication both in vitro and in vivo. We show that silencing of genes believed to be essential for the Kaposi sarcoma-associated herpesvirus (KSHV) latent life cycle (the oncogenic cluster) has a varied effect in PEL cell lines cultured in vitro, however, concomitant silencing of the viral cyclin (vcyclin) and viral FLICE (Fas-associating protein with death domain-like interleukin-1-converting enzyme) inhibitory protein (vFLIP) caused efficient apoptosis in all PEL lines tested. We demonstrate that in a murine model of PEL, lentiviral-mediated RNA interference both inhibits development of ascites and can act as a treatment for established ascites. We also show that the administered lentiviral vectors are essentially limited to the peritoneal cavity, which has advantages for safety and dosage in a therapeutic setting. This shows the use of lentiviral-mediated RNA interference in vivo as a potential therapeutic against a virally driven human cancer. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: T.-S. Huang, J.-Y. Hsieh, Y.-H. Wu, C.-H. Jen, Y.-H. Tsuang, S.-H. Chiou, J. Partanen, H. Anderson, T. Jaatinen, Y.-H. Yu, et al. Functional Network Reconstruction Reveals Somatic Stemness Genetic Maps and Dedifferentiation-Like Transcriptome Reprogramming Induced by GATA2 Stem Cells, May 1, 2008; 26(5): 1186 - 1201. [Abstract] [Full Text] [PDF] E. Wies, Y. Mori, A. Hahn, E. Kremmer, M. Sturzl, B. Fleckenstein, and F. Neipel The viral interferon-regulatory factor-3 is required for the survival of KSHV-infected primary effusion lymphoma cells Blood, January 1, 2008; 111(1): 320 - 327. [Abstract] [Full Text] [PDF] F.-Q. An, H. M. Folarin, N. Compitello, J. Roth, S. L. Gerson, K. R. McCrae, F. D. Fakhari, D. P. Dittmer, and R. Renne Long-Term-Infected Telomerase-Immortalized Endothelial Cells: a Model for Kaposi's Sarcoma-Associated Herpesvirus Latency In Vitro and In Vivo. J. Virol., May 1, 2006; 80(10): 4833 - 4846. [Abstract] [Full Text] [PDF]

	Copyright © 2005 by American Society of Hematology         Online ISSN: 1528-0020